MLSS MILESTONE SCIENTIFIC INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 855683 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY46.6%
TTM EPS YoY55.6%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-40.0%
Net margin-38.3%
FCF margin-16.0%
EBITDA margin-39.2%
Returns
ROE-114.7%
ROA-46.1%
ROIC (approx.)-165.6%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-27.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.97M | $8.63M |
| Cost of revenue | $2.57M | $2.20M |
| Gross profit | $6.41M | $6.43M |
| R&D expense | $449,469 | $858,767 |
| SG&A expense | $11.58M | $12.30M |
| Operating income | -$5.70M | -$6.76M |
| Pretax income | -$5.72M | -$4.71M |
| Net income | -$5.72M | -$4.71M |
| EBITDA | -$5.62M | -$6.72M |
| EPS (basic) | -0.07 | -0.06 |
| EPS (diluted) | -0.07 | -0.06 |
| Weighted avg. shares (diluted) | 82.06M | 79.79M |
| Banking | ||
| Net interest income | — | $60,265 |
| Balance sheet | ||
| Cash & equivalents | $1.11M | $3.26M |
| Short-term investments | — | $0 |
| Receivables | — | $475,376 |
| Inventory | $3.78M | $3.71M |
| Current assets | $7.48M | $9.29M |
| PP&E, net | $19,193 | $12,921 |
| Intangibles | $79,063 | $148,404 |
| Total assets | $7.81M | $9.80M |
| Current liabilities | $3.94M | $3.74M |
| Total liabilities | $4.80M | $3.96M |
| Shareholders' equity | $3.01M | $5.83M |
| Shares outstanding | 80.45M | 78.01M |
| Cash flow statement | ||
| Operating cash flow | -$2.92M | -$2.92M |
| Capital expenditure | $15,124 | $10,124 |
| Free cash flow | -$2.93M | -$2.93M |
| Investing cash flow | -$15,124 | $2.97M |
| Financing cash flow | $786,335 | $233,771 |
| Depreciation & amortization | $78,195 | $37,448 |
| Stock-based compensation | $952,716 | $1.35M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.